 |
12 Diseases |  |
14 Trials |
|
14 Trials |  |
524 News |  |
| «123456789» |
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
New P4 trial: A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study (clinicaltrials.gov) - Feb 28, 2017
P4, N=64, Not yet recruiting, Sponsor: Fundacion SEIMC-GESIDA
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Trial primary completion date: ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection (clinicaltrials.gov) - Feb 28, 2017
P3, N=25, Recruiting, Sponsor: ViiV Healthcare
Trial primary completion date: Feb 2019 --> Oct 2021
- ||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
New P3 trial: Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019 (clinicaltrials.gov) - Jan 10, 2017
P3, N=40, Not yet recruiting, Sponsor: ViiV Healthcare
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Trial completion: Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet (clinicaltrials.gov) - Dec 8, 2016
P1, N=20, Completed, Sponsor: ViiV Healthcare
Trial primary completion date: Feb 2019 --> Oct 2021 Recruiting --> Completed
- |||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Clinical: FLAIR: Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (clinicaltrials.gov) - Nov 17, 2016
P3, N=570, Recruiting, Sponsor: ViiV Healthcare
Recruiting --> Completed Not yet recruiting --> Recruiting
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment open: Lighthouse: Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS). (clinicaltrials.gov) - Nov 1, 2016
P2a, N=40, Recruiting, Sponsor: Neuroscience Trials Australia
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
New P3 trial: FLAIR: Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (clinicaltrials.gov) - Oct 30, 2016
P3, N=570, Not yet recruiting, Sponsor: ViiV Healthcare
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Trial initiation date, Adherence: TAISTR: Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs (clinicaltrials.gov) - Oct 25, 2016
P4, N=50, Not yet recruiting, Sponsor: University College Dublin
Not yet recruiting --> Recruiting Initiation date: Jan 2016 --> Nov 2016
- | Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion: Interaction With HIV Antiretroviral Agents (clinicaltrials.gov) - Oct 20, 2016
P1, N=40, Completed, Sponsor: Bayer
Initiation date: Jan 2016 --> Nov 2016 Recruiting --> Completed
- Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: Interaction With HIV Antiretroviral Agents (clinicaltrials.gov) - Oct 12, 2016
P1, N=40, Recruiting, Sponsor: Bayer
Recruiting --> Completed Trial primary completion date: Apr 2017 --> Oct 2016
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment open: Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet (clinicaltrials.gov) - Oct 7, 2016
P1, N=20, Recruiting, Sponsor: ViiV Healthcare
Trial primary completion date: Apr 2017 --> Oct 2016 Not yet recruiting --> Recruiting
- Tivicay (dolutegravir) / ViiV Healthcare
New trial: Dolutegravir in Reservoirs (clinicaltrials.gov) - Oct 4, 2016
P=N/A, N=40, Recruiting, Sponsor: Emory University
- || Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Trial primary completion date, Adherence: TRIIADD: Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations (clinicaltrials.gov) - Sep 21, 2016
P4, N=100, Recruiting, Sponsor: McGill University Health Center
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2017 --> Sep 2018
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
New P1 trial: Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet (clinicaltrials.gov) - Sep 8, 2016
P1, N=20, Not yet recruiting, Sponsor: ViiV Healthcare
- ||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed: Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed (clinicaltrials.gov) - Jul 29, 2016
P3, N=563, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Sep 2017 --> Sep 2018 Recruiting --> Active, not recruiting
- | Isentress (raltegravir) / Merck (MSD)
Enrollment open, Trial primary completion date, Combination therapy: RALAM: Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine (clinicaltrials.gov) - Jun 30, 2016
P3, N=75, Recruiting, Sponsor: Juan A. Arnaiz
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2016 --> Dec 2016
- ||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed: Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults (clinicaltrials.gov) - Jun 24, 2016
P3, N=600, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2016 --> Dec 2016 Recruiting --> Active, not recruiting
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Trial completion: SCRUM: Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet (clinicaltrials.gov) - May 18, 2016
P1, N=22, Completed, Sponsor: Radboud University
Recruiting --> Active, not recruiting Recruiting --> Completed
- Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: Interaction With HIV Antiretroviral Agents (clinicaltrials.gov) - Apr 27, 2016
P1, N=40, Recruiting, Sponsor: Bayer
Recruiting --> Completed Trial primary completion date: Dec 2016 --> Apr 2017
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment open, Trial primary completion date: SCRUM: Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet (clinicaltrials.gov) - Apr 11, 2016
P1, N=24, Recruiting, Sponsor: Radboud University
Trial primary completion date: Dec 2016 --> Apr 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2016 --> May 2016
- Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment open, Trial primary completion date: Interaction With HIV Antiretroviral Agents (clinicaltrials.gov) - Mar 22, 2016
P1, N=40, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2016 --> May 2016 Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2018 --> Dec 2016
- |||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment open, Trial initiation date, Trial primary completion date, Adherence: TRIIADD: Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations (clinicaltrials.gov) - Mar 22, 2016
P4, N=100, Recruiting, Sponsor: McGill University Health Center
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2018 --> Dec 2016 Not yet recruiting --> Recruiting | Initiation date: Mar 2015 --> Nov 2015 | Trial primary completion date: Sep 2015 --> Sep 2017
- ||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Trial completion: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen (clinicaltrials.gov) - Feb 26, 2016
P3, N=555, Completed, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting | Initiation date: Mar 2015 --> Nov 2015 | Trial primary completion date: Sep 2015 --> Sep 2017 Active, not recruiting --> Completed
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Trial completion: Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD) (clinicaltrials.gov) - Feb 22, 2016
P2, N=53, Completed, Sponsor: Nantes University Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment open, Monotherapy: MONCAY: Study to Evaluate the Efficacy of MONotherapy of TiviCAY (clinicaltrials.gov) - Jan 21, 2016
P3, N=160, Recruiting, Sponsor: Centre Hospitalier R
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
New P4 trial, Adherence: TAISTR: Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs (clinicaltrials.gov) - Jan 20, 2016
P4, N=50, Not yet recruiting, Sponsor: University College Dublin
- Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: Interaction With HIV Antiretroviral Agents (clinicaltrials.gov) - Jan 17, 2016
P1, N=40, Not yet recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2016 --> Jan 2018
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Trial completion: Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects (clinicaltrials.gov) - Dec 21, 2015
P1, N=12, Completed, Sponsor: ViiV Healthcare
Trial primary completion date: Oct 2016 --> Jan 2018 Recruiting --> Completed
- |||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open: Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed (clinicaltrials.gov) - Dec 10, 2015
P3, N=520, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
New P3 trial: Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults (clinicaltrials.gov) - Nov 18, 2015
P3, N=600, Recruiting, Sponsor: Gilead Sciences
- |||||||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
New P3 trial: Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed (clinicaltrials.gov) - Nov 14, 2015
P3, N=520, Not yet recruiting, Sponsor: Gilead Sciences
- || Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
New P3 trial, Monotherapy: MONCAY: Study to Evaluate the Efficacy of MONotherapy of TiviCAY (clinicaltrials.gov) - Nov 5, 2015
P3, N=160, Not yet recruiting, Sponsor: Centre Hospitalier R
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment open: Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects (clinicaltrials.gov) - Oct 22, 2015
P1, N=12, Recruiting, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
New P1 trial: SCRUM: Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet (clinicaltrials.gov) - Oct 6, 2015
P1, N=24, Not yet recruiting, Sponsor: Radboud University
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Trial primary completion date: Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects (clinicaltrials.gov) - Oct 2, 2015
P1, N=12, Not yet recruiting, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2016 --> Nov 2015
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment open, Trial initiation date: PHI 05: Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection (clinicaltrials.gov) - Oct 1, 2015
P=N/A, N=40, Recruiting, Sponsor: Cynthia L Gay, MD
Trial primary completion date: Feb 2016 --> Nov 2015 Not yet recruiting --> Recruiting | Initiation date: Feb 2015 --> Sep 2015
- | Adempas (riociguat) / Bayer, Merck (MSD)
New P1 trial: Interaction With HIV Antiretroviral Agents (clinicaltrials.gov) - Sep 22, 2015
P1, N=40, Not yet recruiting, Sponsor: Bayer
- ||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment change: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen (clinicaltrials.gov) - Sep 21, 2015
P3, N=554, Active, not recruiting, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting | Initiation date: Feb 2015 --> Sep 2015 N=428 --> 554
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
New P1 trial: Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects (clinicaltrials.gov) - Sep 3, 2015
P1, N=12, Not yet recruiting, Sponsor: ViiV Healthcare
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment open: SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over (clinicaltrials.gov) - Aug 23, 2015
P4, N=40, Recruiting, Sponsor: St Stephens Aids Trust
N=428 --> 554 Not yet recruiting --> Recruiting
- ||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment closed, Enrollment change, Trial primary completion date: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen (clinicaltrials.gov) - Aug 11, 2015
P3, N=428, Active, not recruiting, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting | N=538 --> 428 | Trial primary completion date: Apr 2016 --> Apr 2015
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
New P4 trial: SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over (clinicaltrials.gov) - Jul 27, 2015
P4, N=40, Not yet recruiting, Sponsor: St Stephens Aids Trust
- ||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment change, Trial primary completion date: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen (clinicaltrials.gov) - Jul 8, 2015
P3, N=428, Active, not recruiting, Sponsor: ViiV Healthcare
Not yet recruiting --> Active, not recruiting | N=538 --> 428 | Trial primary completion date: Apr 2016 --> Apr 2015 N=538 --> 428 | Trial primary completion date: Oct 2015 --> Apr 2015
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment open: ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection (clinicaltrials.gov) - May 13, 2015
P3, N=25, Recruiting, Sponsor: GlaxoSmithKline
N=538 --> 428 | Trial primary completion date: Oct 2015 --> Apr 2015 Not yet recruiting --> Recruiting
- ||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment open: TRIUMPH: Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany (clinicaltrials.gov) - Apr 20, 2015
P=N/A, N=400, Recruiting, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment closed, Trial primary completion date: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen (clinicaltrials.gov) - Apr 20, 2015
P3, N=538, Active, not recruiting, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Oct 2015
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Clinical: PHI 05: Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection (clinicaltrials.gov) - Mar 10, 2015
P=N/A, N=40, Not yet recruiting, Sponsor: Cynthia L Gay, MD
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment closed: Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD) (clinicaltrials.gov) - Feb 11, 2015
P2, N=53, Active, not recruiting, Sponsor: Nantes University Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Oct 2015 Recruiting --> Active, not recruiting
- ||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
New P4 trial, Adherence: TRIIADD: Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations (clinicaltrials.gov) - Feb 3, 2015
P4, N=100, Not yet recruiting, Sponsor: McGill University Health Center
- ||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Clinical: TRIUMPH: Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany (clinicaltrials.gov) - Jan 22, 2015
P=N/A, N=400, Not yet recruiting, Sponsor: ViiV Healthcare